Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Comparative genomic analyses of attenuated strains of Mycoplasma gallisepticum.

Szczepanek SM, Tulman ER, Gorton TS, Liao X, Lu Z, Zinski J, Aziz F, Frasca S Jr, Kutish GF, Geary SJ.

Infect Immun. 2010 Apr;78(4):1760-71. doi: 10.1128/IAI.01172-09. Epub 2010 Feb 1.

2.

Identification of Strain-Specific Sequences That Distinguish a Mycoplasma gallisepticum Vaccine Strain from Field Isolates.

Ricketts C, Pickler L, Maurer J, Ayyampalayam S, García M, Ferguson-Noel NM.

J Clin Microbiol. 2016 Dec 28;55(1):244-252. doi: 10.1128/JCM.00833-16. Print 2017 Jan.

3.

Extensive variation in surface lipoprotein gene content and genomic changes associated with virulence during evolution of a novel North American house finch epizootic strain of Mycoplasma gallisepticum.

Tulman ER, Liao X, Szczepanek SM, Ley DH, Kutish GF, Geary SJ.

Microbiology. 2012 Aug;158(Pt 8):2073-88. doi: 10.1099/mic.0.058560-0. Epub 2012 May 24.

PMID:
22628486
4.

Identification of lipoprotein MslA as a neoteric virulence factor of Mycoplasma gallisepticum.

Szczepanek SM, Frasca S Jr, Schumacher VL, Liao X, Padula M, Djordjevic SP, Geary SJ.

Infect Immun. 2010 Aug;78(8):3475-83. doi: 10.1128/IAI.00154-10. Epub 2010 Jun 1.

5.

The development and application of a Mycoplasma gallisepticum sequence database.

Armour NK, Laibinis VA, Collett SR, Ferguson-Noel N.

Avian Pathol. 2013;42(5):408-15. doi: 10.1080/03079457.2013.819486. Epub 2013 Jul 26.

PMID:
23889487
6.

Mycoplasma gallisepticum in vivo induced antigens expressed during infection in chickens.

Ron M, Gorelick-Ashkenazi A, Levisohn S, Nir-Paz R, Geary SJ, Tulman E, Lysnyansky I, Yogev D.

Vet Microbiol. 2015 Feb 25;175(2-4):265-74. doi: 10.1016/j.vetmic.2014.12.007. Epub 2014 Dec 18.

PMID:
25575879
7.

Biological characterization of Russian Mycoplasma gallisepticum field isolates.

Sprygin AV, Elatkin NP, Kolotilov AN, Volkov MS, Sorokina MI, Borisova AV, Andreychuk DB, Mudrak NS, Irza VN, Borisov AV, Drygin VV.

Avian Pathol. 2011 Apr;40(2):213-9. doi: 10.1080/03079457.2011.554795.

PMID:
21500042
8.

Hydrogen peroxide production from glycerol metabolism is dispensable for virulence of Mycoplasma gallisepticum in the tracheas of chickens.

Szczepanek SM, Boccaccio M, Pflaum K, Liao X, Geary SJ.

Infect Immun. 2014 Dec;82(12):4915-20. doi: 10.1128/IAI.02208-14. Epub 2014 Aug 25.

9.

Role of the GapA and CrmA cytadhesins of Mycoplasma gallisepticum in promoting virulence and host colonization.

Indiková I, Much P, Stipkovits L, Siebert-Gulle K, Szostak MP, Rosengarten R, Citti C.

Infect Immun. 2013 May;81(5):1618-24. doi: 10.1128/IAI.00112-13. Epub 2013 Mar 4.

10.
11.

Effects of sialidase knockout and complementation on virulence of Mycoplasma gallisepticum.

May M, Szczepanek SM, Frasca S Jr, Gates AE, Demcovitz DL, Moneypenny CG, Brown DR, Geary SJ.

Vet Microbiol. 2012 May 25;157(1-2):91-5. doi: 10.1016/j.vetmic.2011.12.004. Epub 2011 Dec 11.

PMID:
22197303
12.

The oppD Gene and Putative Peptidase Genes May Be Required for Virulence in Mycoplasma gallisepticum.

Tseng CW, Chiu CJ, Kanci A, Citti C, Rosengarten R, Browning GF, Markham PF.

Infect Immun. 2017 May 23;85(6). pii: e00023-17. doi: 10.1128/IAI.00023-17. Print 2017 Jun.

13.

Evaluation of the egg transmission and pathogenicity of Mycoplasma gallisepticum isolates genotyped as ts-11.

Armour NK, Ferguson-Noel N.

Avian Pathol. 2015;44(4):296-304. doi: 10.1080/03079457.2015.1044890.

PMID:
25925422
14.

MalF is essential for persistence of Mycoplasma gallisepticum in vivo.

Tseng CW, Kanci A, Citti C, Rosengarten R, Chiu CJ, Chen ZH, Geary SJ, Browning GF, Markham PF.

Microbiology. 2013 Jul;159(Pt 7):1459-70. doi: 10.1099/mic.0.067553-0. Epub 2013 May 8.

PMID:
23657682
15.

Safety and efficacy of Mycoplasma gallisepticum TS-11 vaccine for the protection of layer pullets against challenge with virulent M. gallisepticum R-strain.

Bíró J, Povazsán J, Korösi L, Glávits R, Hufnagel L, Stipkovits L.

Avian Pathol. 2005 Aug;34(4):341-7.

PMID:
16147571
16.

Safety and efficacy of a Mycoplasma gallisepticum oppD knockout mutant as a vaccine candidate.

Tseng CW, Chiu CJ, Kanci A, Noormohammadi AH, Browning GF, Markham PF.

Vaccine. 2017 Oct 27;35(45):6248-6253. doi: 10.1016/j.vaccine.2017.08.073. Epub 2017 Sep 21.

PMID:
28941621
17.

GapA and CrmA coexpression is essential for Mycoplasma gallisepticum cytadherence and virulence.

Papazisi L, Frasca S Jr, Gladd M, Liao X, Yogev D, Geary SJ.

Infect Immun. 2002 Dec;70(12):6839-45.

18.

Global Changes in Mycoplasma gallisepticum Phase-Variable Lipoprotein Gene vlhA Expression during In Vivo Infection of the Natural Chicken Host.

Pflaum K, Tulman ER, Beaudet J, Liao X, Geary SJ.

Infect Immun. 2015 Nov 9;84(1):351-5. doi: 10.1128/IAI.01092-15. Print 2016 Jan.

19.

Pathologic lesions caused by coinfection of Mycoplasma gallisepticum and H3N8 low pathogenic avian influenza virus in chickens.

Stipkovits L, Glavits R, Palfi V, Beres A, Egyed L, Denes B, Somogyi M, Szathmary S.

Vet Pathol. 2012 Mar;49(2):273-83. doi: 10.1177/0300985811415702. Epub 2011 Aug 8.

PMID:
21825309
20.

GapA+ Mycoplasma gallisepticum ts-11 has improved vaccine characteristics.

Shil PK, Kanci A, Browning GF, Marenda MS, Noormohammadi AH, Markham PF.

Microbiology. 2011 Jun;157(Pt 6):1740-9. doi: 10.1099/mic.0.046789-0. Epub 2011 Feb 10.

PMID:
21310786

Supplemental Content

Support Center